TP53 and non-small cell lung carcinoma: In addition, in EGFR‐mutated NSCLC, comutation of TP53, especially missense mutations, exhibited the trend toward shorter progression‐free survival on EGFR tyrosine kinase inhibitors (TKIs) [29], suggesting that functional p53 is associated with the responsiveness of EGFR‐TKIs.